Status:
COMPLETED
Validation of New Therapeutic Targets to Prevent Collagen Accumulation During Cardiac Fibrosis: Procollagen C-proteinase Enhancers
Lead Sponsor:
Centre Hospitalier Universitaire Dijon
Conditions:
Valvulopathy
Heart Surgery
Eligibility:
All Genders
18-85 years
Phase:
NA
Brief Summary
Heart failure is characterized by cardiac fibrosis linked to extracellular collagen deposits. Collagens are synthesized as soluble precursors, procollagens, which must undergo proteolytic maturation t...
Eligibility Criteria
Inclusion
- Person who has given written consent
- Patient aged 18 to 85 for men and 60 to 85 for women
- Patient requiring cardiac surgery for aortic valve replacement or aortic plastic surgery or aortic plasty or ascending aorta replacement more or less associated with aortic valve surgery
Exclusion
- Person not affiliated or not benefiting from national health insurance
- Person subject to a measure of legal protection (curatorship, guardianship)
- Person deprived of liberty, by judicial or administrative decision
- Major incapable or incapable of giving consent
- Minor
- Pregnant or breastfeeding woman
- Emergency Surgery
- Acute Infectious Endocarditis
Key Trial Info
Start Date :
October 4 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 7 2022
Estimated Enrollment :
66 Patients enrolled
Trial Details
Trial ID
NCT04820959
Start Date
October 4 2020
End Date
July 7 2022
Last Update
February 28 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Dijon Bourgogne
Dijon, France, 21000